Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Pacritinib vs Physician's Choice in Myelofibrosis with Severe Thrombocytopenia
jRCT2031240668Phase 3Active, not recruiting
- Sponsor
- Sobi
- Start
- Jun 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of pacritinib in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and 1 more (2 arms), sponsored by Sobi. Primary endpoints: Spleen volume reduction ≥35% at Week 24 and Total symptom score reduction ≥50% at Week 24. Started Jun 2025; status: active, not recruiting.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on jRCT2031240668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240668.